New GlaxoSmithKline CEO prepares for R&D choices, potential deals

LONDON (Reuters) - Emma Walmsley, GlaxoSmithKline's incoming CEO, will take over Britain's biggest drugmaker at a challenging time but the 47-year-old also inherits the flexibility to do deals and make key choices on new drugs.

New GlaxoSmithKline CEO prepares for R&D choices, potential deals
Read More


Bagikan Berita Ini